[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fusion Antibodies Plc (FAB.LN)

Fusion Antibodies Plc (FAB.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Fusion Antibodies Plc 1 Springbank Road Springbank Industrial Estate Belfast BT17 0QL GBR

https://www.fusionantibodies.com P: 207-933-8780 F: 289-002-0446

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.

Key Statistics

Overview:

Market Capitalization, $K 16,253
Shares Outstanding, K 125,022
% of Insider Shareholders 5.87%
% of Institutional Shareholders 7.56%

Financials:

Annual Sales, $ 1,965 K
Annual Net Income, $ -1,713 K

Growth:

1-Year Return 89.76%
3-Year Return 78.52%
5-Year Return -90.36%
5-Year Revenue Growth -12.79%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.02
Dividend Payout Ratio 0.00%

FAB.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -164.37%
Return-on-Assets % -87.84%
Profit Margin % -87.18%
Debt/Equity N/A
Price/Sales 9.08
Price/Book 22.39
Book Value/Share 0.01
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.